Skip to content

Study · Randomized controlled trial · 2025

6 results

Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.

Gudzune KA, Stefanski A, Cao D, Mojdami D, Wang F, Ahmad N, Ling Poon J

Diabetes, obesity & metabolism4 Nov 2024Cited by 40 (Europe PMC)

PMID39497468 (opens in a new tab)PMCIDPMC11701187 (opens in a new tab)DOI10.1111/dom.16046 (opens in a new tab)PepBankPUB-39497468
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, all tirzepatide groups showed significant improvements in patient-reported outcome scores versus placebo.

    In plain wordsIn adults with obesity or overweight, quality-of-life scores improved more with tirzepatide than with placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreasePatient-reported outcome scores versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All tirzepatide groups demonstrated significant improvements in PRO scores versus placebo.
    2 context sentences
    Summary · context
    The SURMOUNT-1 trial investigated effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on body weight in participants with obesity or overweight.
    Summary · context
    PRO instruments included the Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQOL-Lite-CT), Short Form Survey-36 version 2 (SF-36v2) and EQ-5D-5L.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-1 participants with obesity or overweight, patient-reported outcomes improved incrementally with greater weight reduction, starting from 5% weight reduction.

    In plain wordsIn adults with obesity or overweight, quality-of-life scores improved more as people lost more weight, starting at 5% weight loss.

    Peptide
    Tirzepatide
    Outcome
    IncreasePRO improvement by degree of weight reduction
    Study

    n: not reported in source

    Comparator
    Smaller weight reduction categories
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was a consistent trend of incremental PRO improvement with greater degrees of weight reduction, starting from ≥5% weight reduction.
    2 context sentences
    Summary · context
    The SURMOUNT-1 trial investigated effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on body weight in participants with obesity or overweight.
    Summary · context
    PRO instruments included the Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQOL-Lite-CT), Short Form Survey-36 version 2 (SF-36v2) and EQ-5D-5L.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, participants with 20% or more weight reduction had the greatest change from baseline to week 72 in SF-36v2 Physical Component Summary (4.60).

    In plain wordsIn adults with obesity or overweight, people who lost 20% or more of their weight had the largest physical well-being gain at week 72.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSF-36v2 Physical Component Summary change at 20% or more weight reduction
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    SF-36v2 Physical Component Summary change
    4.6 points
    weight reduction >=20%

    Source sentences

    Summary
    Participants achieving ≥20% weight reduction demonstrated the greatest changes from baseline to week 72 (SF-36v2 Physical Component Summary, 4.60; SF-36v2 Mental Component Summary, 0.80; IWQOL-Lite CT Total score, 24.7).
    2 context sentences
    Summary · context
    The SURMOUNT-1 trial investigated effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on body weight in participants with obesity or overweight.
    Summary · context
    PRO instruments included the Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQOL-Lite-CT), Short Form Survey-36 version 2 (SF-36v2) and EQ-5D-5L.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, participants with 20% or more weight reduction had the greatest change from baseline to week 72 in SF-36v2 Mental Component Summary (0.80).

    In plain wordsIn adults with obesity or overweight, people who lost 20% or more of their weight had the largest mental well-being score change at week 72.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSF-36v2 Mental Component Summary change at 20% or more weight reduction
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    SF-36v2 Mental Component Summary change
    0.8 points
    weight reduction >=20%

    Source sentences

    Summary
    Participants achieving ≥20% weight reduction demonstrated the greatest changes from baseline to week 72 (SF-36v2 Physical Component Summary, 4.60; SF-36v2 Mental Component Summary, 0.80; IWQOL-Lite CT Total score, 24.7).
    2 context sentences
    Summary · context
    The SURMOUNT-1 trial investigated effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on body weight in participants with obesity or overweight.
    Summary · context
    PRO instruments included the Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQOL-Lite-CT), Short Form Survey-36 version 2 (SF-36v2) and EQ-5D-5L.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, participants with 20% or more weight reduction had the greatest change from baseline to week 72 in IWQOL-Lite CT Total score (24.7).

    In plain wordsIn adults with obesity or overweight, people losing 20% or more of their weight had the largest weight-related quality-of-life gain at week 72.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIWQOL-Lite CT Total score change at 20% or more weight reduction
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    IWQOL-Lite CT Total score change
    24.7 points
    weight reduction >=20%

    Source sentences

    Summary
    Participants achieving ≥20% weight reduction demonstrated the greatest changes from baseline to week 72 (SF-36v2 Physical Component Summary, 4.60; SF-36v2 Mental Component Summary, 0.80; IWQOL-Lite CT Total score, 24.7).
    2 context sentences
    Summary · context
    The SURMOUNT-1 trial investigated effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on body weight in participants with obesity or overweight.
    Summary · context
    PRO instruments included the Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQOL-Lite-CT), Short Form Survey-36 version 2 (SF-36v2) and EQ-5D-5L.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-1 participants with obesity or overweight, those with baseline physical and psychosocial limitations had greater improvements in patient-reported outcomes than those without.

    In plain wordsIn adults with obesity or overweight, people with physical or emotional limitations at the start improved more than people without them.

    Peptide
    Tirzepatide
    Outcome
    IncreasePRO improvement in participants with baseline limitations
    Study

    n: not reported in source

    Comparator
    Participants without baseline limitations
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Those with baseline physical and psychosocial limitations experienced greater improvements than those without.
    2 context sentences
    Summary · context
    The SURMOUNT-1 trial investigated effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on body weight in participants with obesity or overweight.
    Summary · context
    PRO instruments included the Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQOL-Lite-CT), Short Form Survey-36 version 2 (SF-36v2) and EQ-5D-5L.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04184622

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Eli Lilly and Companyn = 2,5394 Dec 2019 to 6 Jul 2024

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 24 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.